Simon van der Pol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8035288/publications.pdf

Version: 2024-02-01

1478280 1372474 15 96 10 6 citations h-index g-index papers 15 15 15 183 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. Value in Health, 2017, 20, 388-396.	0.1	29
2	Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application ofÂthe Efficiency Frontier. Value in Health, 2019, 22, 1119-1127.	0.1	13
3	Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. Value in Health, 2019, 22, 1092-1101.	0.1	12
4	School health in Europe: a review of workforce expenditure across five countries. BMC Health Services Research, 2020, 20, 206.	0.9	8
5	Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review. Pharmacoeconomics, 2021, 39, 1411-1427.	1.7	8
6	Health economic evaluation of current vaccination strategies and new vaccines against tuberculosis: a systematic review. Expert Review of Vaccines, 2019, 18, 897-911.	2.0	7
7	Efficiency of Diagnostic Testing for Helicobacter pylori Infections—A Systematic Review. Antibiotics, 2021, 10, 55.	1.5	6
8	Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting. Pharmacoeconomics, 2021, 39, 1355-1363.	1.7	5
9	Perioperative bridging of vitamin K antagonist treatment in patients with atrial fibrillation: only a very small group of patients benefits. Europace, 2019, 21, 716-723.	0.7	4
10	The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance. Pharmacoeconomics, 2022, 40, 823-833.	1.7	2
11	The tripartite insurance model (TIM): a financial incentive to prevent outbreaks of infections due to multidrug-resistant microorganisms in hospitals. Clinical Microbiology and Infection, 2021, 27, 665-667.	2.8	1
12	Diagnostic Testing for Sepsis: A Systematic Review of Economic Evaluations. Antibiotics, 2022, 11, 27.	1.5	1
13	Author's Reply. Value in Health, 2020, 23, 675-676.	0.1	O
14	Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands. European Journal of Health Economics, 2021, 22, 991-999.	1.4	0
15	Evaluations of training and education interventions for improved infectious disease management in low-income and middle-income countries: a systematic literature review. BMJ Open, 2022, 12, e053832.	0.8	O